Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Michel

Showing results (661-670 of 679) with videos related to

Pageof 68
Sort By:
Journal of Neurology|July 29, 2018
Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patientsG Balloy, J Pelletier, L Suchet, et al.
Breast Cancer Research and Treatment|November 21, 2022
Return of individual genomic research results within the PRAEGNANT multicenter registry studyHanna Huebner, Matthias Ruebner, Christian Kurbacher, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2022
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registryVolkmar Müller, Alexander Hein, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT RegistryAndreas D Hartkopf, Christina B Walter, Hans-Christian Kolberg, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
ESMO Open|November 24, 2022
COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapyC Pixberg, M Zapatka, M Hlevnjak, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANTTobias Engler, Peter A Fasching, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Pageof 68

Showing results (661-670 of 679) with videos related to

Sort By:
Pageof 68
Journal of Neurology|July 29, 2018
Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patientsG Balloy, J Pelletier, L Suchet, et al.
Breast Cancer Research and Treatment|November 21, 2022
Return of individual genomic research results within the PRAEGNANT multicenter registry studyHanna Huebner, Matthias Ruebner, Christian Kurbacher, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2022
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registryVolkmar Müller, Alexander Hein, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT RegistryAndreas D Hartkopf, Christina B Walter, Hans-Christian Kolberg, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
ESMO Open|November 24, 2022
COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapyC Pixberg, M Zapatka, M Hlevnjak, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANTTobias Engler, Peter A Fasching, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Pageof 68